Olworm 400mg Tablet (Albendazole)

Description

Olworm 400mg Tablet (Albendazole) — Complete Clinical and Patient Information Guide

Product Overview

Olworm 400mg Tablet (Albendazole) contains Albendazole 400mg as its active pharmaceutical ingredient, belonging to the broad-spectrum benzimidazole anthelmintic (anti-worm agent) — squalene epoxidase/tubulin polymerisation inhibitor in helminths. It is clinically indicated for intestinal helminth infections: ascariasis (roundworm), trichuriasis (whipworm), hookworm infections (ancylostomiasis), enterobiasis (pinworm/threadworm), strongyloidiasis; systemic parasitic infections: neurocysticercosis, echinococcosis (hydatid disease), toxocariasis, giardiasis. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Olworm provides albendazole 400mg — a WHO essential medicine for broad-spectrum anthelmintic treatment of intestinal and systemic parasitic infections.

About Olworm 400mg Tablet and Its Active Ingredient

Albendazole 400mg is the pharmacologically active compound in Olworm 400mg Tablet, a well-established cardiovascular or therapeutic agent with a clinical evidence base developed across decades of research. All cardiovascular and hormonal pharmacotherapy requires physician supervision — drug interactions, contraindications, and dose optimisation decisions require professional medical assessment. Never start, change, or stop these medications without consulting your prescribing physician.

Mechanism of Action

Albendazole is a broad-spectrum benzimidazole anthelmintic active against a wide range of intestinal and tissue nematodes and cestodes. Its mechanism targets tubulin polymerisation in parasitic organisms: albendazole binds selectively to beta-tubulin in helminths, preventing tubulin polymerisation into microtubules. This disrupts the microtubule-dependent glucose uptake in the parasite’s intestinal cells (causing glucose depletion and energy starvation), impairs cell division (mitosis requires microtubule spindle formation), and damages the parasite’s absorptive surface. Albendazole’s much lower affinity for mammalian tubulin (compared to helminth tubulin) provides selective parasite toxicity with a wide therapeutic margin for humans. A single 400mg dose is effective against most intestinal roundworms (Ascaris, hookworm, whipworm, Enterobius), while higher doses for 3–28 days are used for tissue infections (neurocysticercosis, echinococcosis, toxocariasis).

Clinical Indications

Olworm 400mg Tablet (Albendazole) is indicated for:

• Primary indication: intestinal helminth infections: ascariasis (roundworm), trichuriasis (whipworm), hookworm infections (ancylostomiasis), enterobiasis (pinworm/threadworm), strongyloidiasis; systemic parasitic infections: neurocysticercosis, echinococcosis (hydatid disease), toxocariasis, giardiasis
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of therapy.

Dosage and Administration

Single-dose treatment for most intestinal worms: one tablet (400mg) as a single dose. For neurocysticercosis: 400mg twice daily for 8–30 days (with anti-inflammatory treatment). For echinococcosis: 400mg twice daily for 28 days, repeated in cycles. Take with fatty meal for systemic infections — food increases albendazole absorption approximately 5-fold.

Who Should Use Olworm 400mg Tablet

Olworm 400mg Tablet is appropriate for patients confirmed by a qualified healthcare professional to have the conditions listed in the indications section, in whom this specific formulation is clinically appropriate following benefit-risk assessment with no absolute contraindications.

Contraindications

Hypersensitivity to benzimidazoles. Pregnancy (teratogenic in animals — avoid in first trimester; use with caution in second/third trimester only when clearly necessary). Children under 1 year (limited safety data).

Drug Interactions

Cimetidine: increases albendazole sulphoxide plasma levels. Ritonavir/praziquantel: increase albendazole levels. Dexamethasone: increases albendazole sulphoxide levels — used deliberately in neurocysticercosis (inflammation management). Theophylline: albendazole may increase theophylline levels.

A complete medication review is essential before initiating Olworm 400mg Tablet. Cardiovascular and hormonal drugs have numerous clinically significant interactions that can be dangerous if unidentified. Patients must inform all healthcare providers of their complete medication list.

Adverse Effects

Single-dose intestinal: generally very well tolerated — occasional mild GI effects (nausea, abdominal pain). Prolonged therapy for systemic infections: elevated liver enzymes (monitor LFTs), leucopenia (monitor FBC), headache. Neurocysticercosis: initial treatment may worsen neurological symptoms transiently as cysts die and inflammatory response occurs — anti-inflammatory co-treatment (corticosteroids) required.

Special Population Considerations

Pregnancy and deworming: WHO’s deworming programmes in endemic areas use albendazole during the second and third trimesters (benefits of deworming outweigh risks in high-burden settings). In individual clinical practice, avoid in first trimester and use caution thereafter. Food interaction for systemic infections: For neurocysticercosis and echinococcosis, take with a fatty meal (high-fat content substantially increases albendazole absorption and systemic drug levels — critical for efficacy against tissue parasites). For intestinal worm infections, food is less important. LFT monitoring: Required for prolonged therapy courses in systemic infections.

Storage

Store Olworm 400mg Tablet at room temperature (15–25°C) away from direct sunlight, heat, and moisture. Keep in original packaging. Maintain out of reach of children. Do not use beyond expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop cardiovascular medications abruptly without medical advice.

Q: Should I take albendazole with food?
A: For intestinal worm infections, albendazole can be taken with or without food. However, for systemic parasitic infections (neurocysticercosis, echinococcosis), albendazole should always be taken with a fatty meal — dietary fat increases albendazole absorption approximately 5-fold, dramatically improving tissue drug levels needed to effectively kill deeply located cysts and larvae. This is one of the most clinically important food-drug instructions for albendazole.

Evidence Base and Clinical Guidelines

The active ingredient in Olworm 400mg Tablet has been evaluated in landmark randomised controlled trials and is supported by international cardiovascular guidelines from the ESC, ACC/AHA, NICE, and national specialist bodies. Evidence-based cardiovascular pharmacotherapy has transformed outcomes for hypertension, angina, heart failure, and arrhythmia management. GMP-compliant manufacturing ensures consistent product quality and safety.

Cardiovascular Disease Management Context

Pharmacological therapy delivers best outcomes when integrated with lifestyle modification: Mediterranean-style diet, regular aerobic physical activity (150 minutes/week moderate intensity), smoking cessation, alcohol moderation, and sodium restriction for hypertension and heart failure. The combination of optimal pharmacotherapy and sustained lifestyle change produces cardiovascular risk reduction far exceeding either approach alone. Regular follow-up monitoring — blood pressure recording, ECG, renal function and electrolytes — is essential to optimise therapy and detect adverse effects early.

Fixed-dose combination antihypertensive tablets — such as many products in this range — significantly improve treatment adherence, which is the single most common reason for inadequate blood pressure control in treated hypertensive patients. Multiple studies demonstrate that every 10mmHg sustained reduction in systolic blood pressure reduces major cardiovascular event risk by approximately 20%, providing strong motivation for achieving and maintaining blood pressure targets.

Patient Counselling Key Points

• Do not stop abruptly: Beta-blockers, antianginals, and antihypertensives must be withdrawn gradually under medical supervision — abrupt withdrawal risks angina rebound, hypertensive crisis, or cardiac decompensation.
• Monitor blood pressure: Home blood pressure monitoring at the same time daily provides valuable data for dose optimisation — target below 130/80 mmHg in most guidelines for hypertensive patients with cardiovascular disease.
• Carry medication list: All patients on cardiovascular medications should carry a complete medication list for surgical, dental, and emergency care encounters where drug interactions are critical.

Gynaecological and Parasitological Considerations

For clomiphene citrate (ovulation induction): Female infertility affects approximately 1 in 6 couples globally. Anovulation — the failure to release an egg — accounts for approximately 30–40% of female infertility. PCOS (polycystic ovary syndrome) is the most common cause of anovulatory infertility, affecting 8–12% of women of reproductive age. Clomiphene citrate remains the first-line pharmacological treatment for ovulation induction in anovulatory women, with decades of evidence supporting its safety and efficacy. For women who do not respond to clomiphene (approximately 20–25% of PCOS patients), subsequent options include letrozole (showing evidence of higher live birth rates in PCOS), gonadotrophin injections, and assisted reproductive technologies (IVF/ICSI).

For albendazole (anthelmintic): Helminthic infections affect approximately 1.5 billion people globally, predominantly in low- and middle-income countries. Soil-transmitted helminths (Ascaris, hookworm, Trichuris) account for the majority of cases, causing anaemia, malnutrition, impaired cognitive development, and reduced work productivity. WHO recommends periodic deworming with albendazole or mebendazole as a public health intervention in endemic areas. For individual clinical treatment, the choice between single-dose treatment for intestinal helminths and prolonged courses for systemic infections requires accurate diagnosis and appropriate specialist guidance.

For liothyronine (thyroid hormone): Hypothyroidism affects approximately 2–5% of adults globally, with subclinical hypothyroidism occurring in an additional 4–8%. The vast majority of hypothyroid patients achieve adequate thyroid function with levothyroxine (T4) monotherapy. The question of adding T3 (liothyronine) for patients who remain symptomatic despite normal TSH on optimal T4 is an active area of clinical debate — some patients have impaired peripheral T4-to-T3 conversion, and a subset appears to benefit from combination T4+T3 therapy. This requires specialist endocrinological assessment and careful, individualised management.

Evidence Base and Quality Standards

All active ingredients in this product range have been evaluated in randomised controlled trials, systematic reviews, and regulatory submissions reviewed by competent health authorities. GMP-compliant manufacturing ensures consistent product quality across all batches. Patients should obtain prescription medications only from licensed pharmacies with valid prescriptions.

Blood Pressure Targets and Monitoring

Current major cardiovascular guidelines (ESC/ESH 2023, ACC/AHA 2017) recommend the following blood pressure targets for hypertensive patients: general adult population with uncomplicated hypertension, target below 130/80 mmHg; patients aged ≥65 years, target 130–139/70–79 mmHg (avoiding over-treatment which may paradoxically increase risk through J-curve phenomena); patients with CKD and proteinuria, target below 130/80 mmHg; patients with coronary artery disease and stable angina, target 130/80 mmHg or lower; patients with diabetes mellitus, target below 130/80 mmHg.

Home blood pressure monitoring (HBPM) and 24-hour ambulatory BP monitoring (ABPM) are recommended over office BP measurements alone for treatment decisions — office measurements overestimate true BP (white coat hypertension) in approximately 15–30% of patients and underestimate it (masked hypertension) in others. ABPM or HBPM provides more accurate cardiovascular risk assessment and better treatment optimisation.

Patient Counselling Summary

Key points for all patients on antihypertensive and cardiovascular medications: Take medications at the same time daily for consistent drug levels. Never skip doses — cardiovascular medications require consistent daily use for their full protective benefit. Never stop medications abruptly — particularly beta-blockers (rebound angina/hypertension risk) and antianginal drugs. Monitor blood pressure at home at the same time each day in a relaxed, seated position after 5 minutes rest. Report side effects promptly — many can be managed with dose adjustment or substitution rather than discontinuation. Maintain lifestyle modifications: salt restriction (below 6g/day), DASH or Mediterranean diet, regular moderate-intensity aerobic exercise (150 minutes/week), smoking cessation, and alcohol moderation. Attend all scheduled follow-up appointments for blood pressure recording, ECG, and biochemical monitoring as indicated.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It does not replace professional medical advice from a qualified physician, cardiologist, endocrinologist, gynaecologist, or pharmacist. Drug therapy decisions must be individualised. Self-diagnosis and self-treatment of cardiovascular, hormonal, and parasitic conditions can be dangerous. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.